Evolent Health, Inc. Form SC 13G/A January 24, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 02)*

Evolent Health, Inc.

(Name of Issuer)

Class A Common Stock, par value \$0.01 per share

(Title of Class of Securities)

30050B101

(CUSIP Number)

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- x Rule 13d-1(b)
- o Rule 13d-1(c)
- o Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*} The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

30050B101 No. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 1 JPMORGAN CHASE & CO 13-2624428 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) 2 (a) o (b) o SEC USE ONLY 3 CITIZENSHIP OR PLACE OF ORGANIZATION 4 Delaware **SOLE VOTING POWER** 5 6,178,433 NUMBER OF SHARED VOTING POWER **SHARES** BENEFICIALLY 6 OWNED BY 0 **EACH** REPORTING SOLE DISPOSITIVE POWER PERSON WITH: 7 7,116,321 SHARED DISPOSITIVE POWER 8 0 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9

7,116,321

Edgar Filing: Evolent Health, Inc. - Form SC 13G/A

10	INSTRUCTIONS)
	0
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	9.0%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	НС
	FOOTNOTES

Item 1.			
		(a)	Name of Issuer Evolent Health, Inc.
	(b)		Address of Issuer's Principal Executive Offices 800 NORTH GLEBE RD, SUITE 500 ARLINGTON, VA. 22203
Item 2.			
		(a)	Name of Person Filing JPMORGAN CHASE & CO
	(b)	Addres	s of Principal Business Office or, if none, Residence 270 Park Avenue New York, NY 10017
		(c)	Citizenship Delaware
		(d)	Title of Class of Securities lass A Common Stock, par value \$0.01 per share
		(e)	CUSIP Number 30050B101
Item 3. If this state a:	ement is file	d pursuant to §§2	240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is
(a)	O	Broker or de	ealer registered under section 15 of the Act (15 U.S.C. 78o).
(b)	0	Ban	k as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)	0	Insurance compa	any as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d) o Investmer	nt company r	egistered under s	section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
(e)	0	An inve	estment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f) o	An emplo	oyee benefit plan	or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g) x	A parent	holding compan	y or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h) o A saving	s association	ns as defined in S	Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
•		luded from the d t of 1940 (15 U.S	efinition of an investment company under section 3(c)(14) of the S.C. 80a-3);

Edgar Filing: Evolent Health, Inc. - Form SC 13G/A

- (j) o A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
- (k) o A group, in accordance with $\$ 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with $\$ 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4.		Ownership.				
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.						
	(a)	Amount beneficially owned: 7,116,321				
(b)		(b) Percent of class: 9.0%				
	(c)	Number of shares as to which the person has:				
	(i)	Sole power to vote or to direct the vote: 6,178,433				
	(ii)	Shared power to vote or to direct the vote: 0				
	(iii)	Sole power to dispose or to direct the disposition of: 7,116,321				
	(iv)	Shared power to dispose or to direct the disposition of: 0				
Item 5.		Ownership of Five Percent or Less of a Class				
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.						
Not applical	ble					
Item 6.	6. Ownership of More than Five Percent on Behalf of Another Person.					
Not applical	ble					
Item 7.	17. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company					
J.P. Morgan Investment Management Inc. ; JPMorgan Chase Bank, National Association ; JPMorgan Asset Management (UK) Limited ; J.P. Morgan Securities LLC						
Item 8.	Identification and Classification of Members of the Group					
Not applical	ble					
Item 9.	Notice of Dissolution of Group					
Not applicable						

Edgar Filing: Evolent Health, Inc. - Form SC 13G/A

Item Certification 10.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

JPMorgan Chase & Co.

Date: January 24, 2019 By: /s/ Rachel Tsvaygoft

Name: Rachel Tsvaygoft Title: Vice President

Footnotes:

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)